EZH2 and prostate neoplasm: Although significant progress has been made toward understanding the function and deregulation of EZH2 in PCa cells in vitro and prostate tumors in vivo, it remains largely unclear regarding how the novel regulatory mechanisms of EZH2 can be translated to effectively kill CRPC cells.